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Introduction 53 54
Skeletal muscle growth involves a net accumulation of protein, with rates of protein synthesis 55 exceeding that of degradation. One of the key systems regulating this balance is the insulin-like 56 growth factor (Igf) The objective of this study was to improve our understanding of how the Igfbp gene family is 122 regulated by a range of physiological stimuli known to induce remodelling of skeletal muscle mass. 123
We quantified the transcriptional responses of the complete repertoire of expressed Igfbps in primary 124 differentiated fast-twitch skeletal muscle cultures from Atlantic salmon (Salmo salar L.) using four 125 experimental models that induced a catabolic or anabolic status, via pathways regulated by 126 dexamethasone, proinflammatory cytokines, amino acids and Igf-I. Our results show distinct stimuli 127 result in divergent and complex expression responses of Igfbp family member genes during muscle 128 remodelling, including evolutionary divergence of salmonid-specific gene duplicates. and a pilot study was carried out to test different concentrations (data not shown). Myotubes were 159 incubated in bovine serum free media for two hours to reduce gene expression to basal levels before 160 +DEX and +IL-1β treatments. Total RNA was extracted (section 2.4) at 0, 1, 3, 6, 24 and 48 hours 161 post-treatment. For the AA-treatment, a modified culture media with no amino acids was used 162 (Garcia de la serrana and Johnston, 2013) and total RNA extracted at 0, 1, 3, 6, 24 and 48 hours. The 163 anabolic treatment (+AA+Igf-I) involved a restitution of amino acids in the -AA cell culture media 164 (at 48 hours) combined with 100nM of recombinant Atlantic salmon Igf-I (GROPEP, Australia). 165
Total RNA from the +AA+Igf-I treatment was collected 3, 6 and 24 hours after the +AA+Igf-I 166 treatment. In all cases, myotubes with normal free-serum DMEM media were maintained in parallel 167 as controls (-DEX, -IL-1β, +AA and +AA-Igf-I) for each of the conditions tested and sampled at the 168 same time as treated cells. 169 170
RNA extraction and cDNA synthesis 171
Total RNA was extracted from two wells per time-point, per treatment and culture using an RNeasy 172 extraction kit (Qiagen, Manchester, UK), following the manufacturers protocol. RNA concentrations, 173 230/260 and 280/260 ratios were determined using a Nanodrop 1000 spectrophotometer (Nanodrop, 174
ThermoFisher Scientific). RNA with respective 260/280 and 260/280 ratios over 1.8 and 2 was used 175 for cDNA synthesis. 250ng of RNA was reverse transcribed for each sample using a Quantitech kit 176 (Qiagen), following the manufacturers guidelines, including a step to remove residual genomic DNA. 177
Control samples with RNA but no reverse transcriptase (-RT) were included. The 1:1 first-strand 178 cDNA was diluted 40x and stored at -20 o C until use in quantitative PCR (qPCR) (section 2.6). A pool 179 of all first-strand cDNAs generated was used as an interplate calibrator (IPC) for qPCR analysis 180
(section 2.6). 181
Primer design 183
Primers used for amplification of the complete salmonid Igfbp family (19 genes), as well as mafbx, 184 murf1, igf2, myl1, tnni1 and the housekeeping genes hprt1, rpl4, rps13, rps29 have been described 
Effect of catabolic and anabolic treatments on myotube diameter 275
The effect of the different treatments on salmon myotube morphology and cytoskeleton arrangement 276 was assessed 24 and 48 hours after treatment using bright field microscopy and immunofluorescence 277 against actin and desmin filaments ( Figure 1A Considering that we used differentiated myotubes as the starting point for each treatment, a reduction 282 in the number of myotubes, coupled with an increase in the number of single cells, might be 283 explained by a dramatic reduction in the integrity of the myotube cytoskeleton. In other words, the 284 apparent single cells may actually remain part of myotubes where the cytoskeleton has undergone 285 extensive atrophy. Bright-field microscopy ( Figure 1A , d, i) and desmin immunofluorescence ( Figure1A , h, p) showed that the addition of amino acids and Igf-I (+AA+Igf) to myotubes under amino acid 287 deprivation for 48h (-AA-48h) ( Figure 1A , d, h) induced myotube hypertrophy ( Figure 1A , i, p). 288
289
To quantify the accompanying phenotypic changes in myotubes, we compared myotube diameters for 290 all treatments against controls. +DEX and -AA treatments reduced myotube diameter by ~30-40% at 291 24 and 48 hours compared to controls (all P < 0.001) ( Figure 1B and C). The +IL-1β treatment 292 reduced myotube diameter by ~10% at 24 hours (P = 0.055) and by ~30% at 48 hours (P < 0.001) 293
( Figure 1D ). When amino acids and Igf-I were added to the -AA culture (-48h time-point), myotube 294 diameter increased to pre-treatment values in 24h (P < 0.001) ( Figure 1B ). These data confirm that 295 the treatments induced the intended myotube phenotypic changes, which provides a robust platform 296 to interpret gene expression responses measured in the same experimental samples (section 3.2). 297 298
Gene expression responses to catabolic and anabolic stimuli 299
Genes encoding all 19 Igfbps were quantified using qPCR in Atlantic salmon myotubes, but 10 were 300 not detected, namely igfbp1a2, igfbp1b1, igfbp2b1, igfbp2b2, igfbp3a2, igfbp3b1, igfbp3b2, igfbp6a2 301 and igfbp6b1. Given that the relevant primers have been verified in past studies where expression of 302 all 19 genes was reported (e.g. Macqueen et al. 2013; Alzaid et al. 2016b), we concluded that these 303 igfbp genes were not expressed in salmon myotubes. In parallel, genes encoding two E3-ubiquitin 304 ligases (mafbx, murf1), two fast-twitch skeletal muscle sarcomere components (myosin light chain, 305 myl1 and troponin I, tnni1), the Igf-II hormone (igf2) and two autophagy related genes (atg4b1, 306 atg4b2) were also analysed. 307 308 3.2.1. +DEX treatment 309 10 of the 16 tested genes were significantly regulated by the +DEX treatment compared to controls 310 (P <0.05 for treatment effect), including those encoding 6 of the 10 expressed Igfbp family members, 311 both tested E3 Ubiquitin ligases, one of the atg4b paralogues and igf2 (Table 1 ). In addition, 4 of the10 genes with a significant treatment effect showed a significant treatment*time-point interaction, 313 indicating marked differences in the response to dexamethasone at different time-points (Table 1) . 314
Among these were two genes encoding Igfbp6 family members (igfbp6a1 and igfbp6b2), which 315 showed reciprocal responses across the treatment time course. Specifically, comparing +DEX to 316 control cultures, igfbp6a1 was most highly downregulated, while igfbp6b2 was most highly 317 upregulated at later time-points (24 to 48 hours) of the culture (Figure 2A, B) , where atrophy was 318 evident (Figure 1B-D) . A similar pattern was observed for two Igfbp5 family members, with igfbp5a 319 being downregulated at 24 to 48 hours post treatment and igfbp5b1 being strongly induced from 6 320 genes showed highly distinct responses to the +DEX treatment ( Figure 2G, H) . Specifically, mafbx 324 was induced from early stages of the culture (before notable changes in myotube diameter were 325 observed), through to 24 hours, when atrophy was first observed ( Figure 1C ) but returned to control 326 levels by 48 hours ( Figure 2G ). Conversely, murf1 was induced relative to control levels at 24 and 48 327 hours sampling points ( Figure 2H ). In addition, both igf2 and atgb42 were markedly induced at 24 328 and 48 hours post +DEX treatment ( Figure 2I, H) . 329 330 Therefore, the most pronounced changes in gene expression responses to dexamethasone occurred at 331 stages of the culture (post-6 hours), when myotube remodelling was evident. 332 333
+IL-1β treatment 334
Despite our observation that myotube diameter decreased significantly in response to the +IL-1β 335 treatment by 48 hours (Figure 1D ), only 2 of the 16 tested genes were significantly regulated during 336 this remodelling of myotube phenotype (Table 2; Figure 3 ). This included igfbp1a1, which wasdownregulated at 3, 6 and 48 hours post-treatment, but not other time-points (Table 2; Figure 3A) . In 338 contrast, murf1 was increased in response to controls, most notably at 48 hours ( Figure 3B) . 339 340
-AA treatment 341
The -AA treatment was accompanied by significant responses in only 3 of the 16 tested genes (Table  342 3; Figure 4 ), despite clear evidence of myotube atrophy ( Figure 1B) . Two of the genes significantly 343 regulated by the -AA treatment were the same Igfbp6 family members that were strongly affected by 344 dexamethasone (section 3.2.2). Specifically, both igfbp6a1 and igfbp6b2 were downregulated during 345 the -AA treatment time course relative to controls (Table 3) , with igfbp6a1 being particularly 346 strongly affected from 6 hours post treatment ( Figure 4A, B) . The other gene significantly affected by 347 the -AA treatment, mafbx, was downregulated at many sampled time-points (Table 3; Figure 4C ). 348 349
+AA+Igf-I treatment 350
The +AA+Igf-I treatment, which was accompanied by a significant recovery of myotube diameter 351 Here we addressed the regulation of Igfbp gene expression in skeletal muscle remodelling, which is 362 poorly understood in teleost fish. Our study is the first to systematically document the regulation of 363
full knowledge of gene paralogues retained from both the teleost and salmonid-specific WGD events, 365 which if ignored can limit physiological interpretations of gene expression (Johnston et al. 2011) . 366
Though all three tested catabolic signals (i.e. dexamethasone, IL-1β and amino acid deprivation) 367 induced atrophy of differentiated myotubes (Figure 1 
Dexamethasone-induced atrophy of salmon myotubes (Figure 1 ) was accompanied by a complex 376 expression response of different Igfbp genes (Figure 2) . The catabolic state of the myotubes was also 377 evidenced by upregulation of mafbx, murf1 and atg4b1 (Table 1) , suggesting activation of the 378 proteasome and autophagy systems. However, we also observed Igf system expression responses that 379 are difficult to reconcile with a purely catabolic state, particularly the upregulation of igf2, igfbp4 and 380 igfbp5b1 (Table 1) However, as we cultured myocytes for 10 days before IL-1β treatment, our study represents a more 416 advanced state of differentiation (Bower et al., 2010; Bower and Johnston, 2010; Garcia de la serrana 417 et al., 2013). Thus, the discrepancies between our study and these past investigations presumably 418 reflect differences in both the concentrations of IL-1β used, but potentially also the ontogeny of the 419 cell culture. Interestingly, in another study, a strong upregulation of Igfbp6a2 was observed in 420 rainbow trout (Oncorhynchus mykiss) following in vivo bacterial challenge at the fry stage, a response 421 that was strikingly correlated to that of master genes regulated by proinflammatory cytokine 422 pathways, including IL-1β (Alzaid et al. 2016b). However, in that past study, the tissues responsible 423 for igfbp6a2 upregulation were not determined and whether skeletal muscle was involved remains 424 unknown. In our study, igfbp1a2 (the single Igfbp1 family member expressed in myotubes) was 425 slightly downregulated in response to IL-1β (Table 2) . However, its salmonid-specific paralogue 426 igfbp1a2 is robustly induced during bacterial infection, which is presumed to restrict Igf hormones in 427 As for IL-1β, we observed a paucity of transcriptional responses in atrophic salmon myotubes 437 deprived of amino acids (Table 3) , similar to previous reports (Bower and Johnston, 2010). However, 438 a separate past study showed that the E3-Ubiquitin ligase mafbx was robustly induced by the same 439 treatment (Bower et al. 2010), which was not observed in our data. The only other genes that 440 responded to amino acid deprivation were igfbp6a1 and igfbp6b2 ( Figure 4A , B), which were eachstrongly decreased, which contrasts with the fact that Igfbp6 is a negative regulator of Igf signalling, 442 particularly through Igf-II, which in mammals binds Igfbp6 with much higher affinity than Igf-I 443 Southgate, R.J., Neil, B., Prelovsek, O., El-Osta, A., Kamei, Y., Miura, S., Ezaki, O., et al. 2007 . 671 -1β (a, e, i, m), -AA (b, f, j, n), +DEX (c, g, k, o) and +AA+Igf-I (d, h, l, p responses for all genes tested in the study is provided in Table 2 . expression responses for all genes tested in the study is provided in Table 3 . expression responses for all genes tested in the study is provided in Table 4 . 727 728 Supplementary File 1. Myotube morphology in response to catabolic and anabolic treatments. 729
Bright field microscopy or immunofluorescence against desmin (red) and actin (green) filaments for 730 myotubes under different experimental conditions. All pictures were taken using x20 magnification. 731
The scale bar for each picture represents 150µm. 
761
Genes showing a statistically significant response to amino acids deprivation (-AA) treatment are underlined.
762
All values where the -AA treatment is divided by the control show fold change in transcript levels 
773
* refers to myotubes being maintained for 48 hours in media free of amino acids for 48 hour before adding amino acids and Igf-I growth factor (+AA +Igf-I) treatment
774
Genes showing a statistically significant response to +AA +Igf-I treatment are underlined.
775
All values where the +AA +Igf-I treatment is divided by the control show fold change in transcript levels 776 n/a: treatment*time-point interaction not assessed (Kruskal-Wallis test applied).
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